HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Thoracic Surgery174 papers

Hyperacute rejection of cardiac transplant

Last edited: 3 h ago

Overview

Hyperacute rejection (HAR) of cardiac transplants is an immediate and severe immune response that occurs within minutes to hours after transplantation due to pre-existing antibodies in the recipient recognizing non-self antigens on the donor organ. This rapid rejection is primarily mediated by the recipient's innate and adaptive immune systems, particularly through complement activation and T-cell responses. It significantly impacts graft survival and patient outcomes, often leading to irreversible damage if not promptly addressed. HAR is particularly critical in xenotransplantation scenarios, such as pig-to-human heart transplants, where pre-existing xenoreactive antibodies pose a substantial barrier. Understanding and managing HAR is crucial for clinicians to optimize transplant outcomes and improve patient survival rates in both allo- and xenotransplantation settings. 1 6

Pathophysiology

Hyperacute rejection is driven by the rapid activation of the recipient's immune system upon exposure to foreign antigens on the donor organ. In the context of cardiac transplants, this process typically involves several key mechanisms:

Complement Activation: Pre-existing antibodies, often directed against Galα1-3Gal epitopes in xenotransplantation or specific HLA antigens in allotransplantation, bind to the donor tissue. This binding activates the complement system, leading to the formation of membrane attack complexes (MAC) that cause immediate cellular damage and inflammation. 1 6

T-Cell Mediated Rejection: Alongside complement activation, T-cells recognize and respond to alloantigens presented by donor major histocompatibility complex (MHC) molecules. This leads to the recruitment and activation of additional immune cells, exacerbating the inflammatory response and further damaging the graft. 2 6

Inflammatory Cascade: The initial complement activation triggers a cascade of inflammatory mediators, including cytokines and chemokines, which recruit neutrophils and macrophages to the site of injury. These cells contribute to tissue destruction through the release of proteolytic enzymes and reactive oxygen species. 4 6

Ischemia-Reperfusion Injury: Even in the absence of pre-existing antibodies, the inherent ischemia-reperfusion injury during transplantation can amplify the inflammatory response, making the graft more susceptible to rapid rejection if immune activation is already primed. 4 6

These interconnected pathways underscore the urgency in identifying and mitigating HAR to preserve graft viability and function. 1 6

Epidemiology

The incidence of hyperacute rejection is relatively rare in modern clinical practice due to stringent pre-transplant screening and the use of advanced immunosuppressive strategies. However, it remains a significant concern, particularly in xenotransplantation scenarios where the risk is heightened due to xenoreactive antibodies. In allotransplantation, the risk is mitigated by thorough crossmatch testing, but it can still occur in sensitized patients with pre-existing donor-specific antibodies. Specific incidence figures are not widely reported in recent literature, but trends indicate a decline with improved immunological screening and immunosuppressive protocols. 1 6

Age, sex, and geographic factors do not significantly alter the risk profile for HAR, though patient sensitization status and prior transplant history are critical risk factors. The scarcity of donor hearts further complicates the situation, emphasizing the need for meticulous pre-transplant evaluations to avoid such acute rejections. 1 6

Clinical Presentation

Hyperacute rejection manifests rapidly, often within minutes to hours post-transplant, presenting with severe clinical signs indicative of acute graft dysfunction:

Hemodynamic Instability: Rapid onset of hypotension, arrhythmias, and shock.

Cardiac Dysfunction: Marked decline in cardiac output, pulmonary edema, and acute respiratory distress.

Systemic Inflammatory Response: Fever, leukocytosis, and elevated inflammatory markers such as C-reactive protein (CRP) and cytokines like TNF-α and IL-6.

Graft Edema and Necrosis: Visible signs of graft swelling, tenderness, and early signs of necrosis on imaging or gross examination.

Red-flag features include sudden deterioration in graft function without an identifiable cause, which necessitates immediate suspicion of HAR and prompt diagnostic evaluation. 1 6

Diagnosis

The diagnosis of hyperacute rejection relies on a combination of clinical suspicion and specific diagnostic tests:

Clinical Suspicion: Rapid onset of graft dysfunction post-transplant, particularly in sensitized patients or xenotransplantation scenarios.

Laboratory Tests:

- Complement Activation Products: Elevated levels of C3d, C4d, and terminal complement complex (TCC) in graft biopsy or serum. - Inflammatory Markers: Elevated white blood cell count, CRP, and cytokine levels.

Imaging: Echocardiography or other imaging modalities showing signs of graft edema, dysfunction, or early necrosis.

Histopathology:

- Endomyocardial Biopsy: Characteristic findings include intense complement deposition, neutrophilic infiltration, and early cellular necrosis. - Cutoff Values: Specific thresholds for complement activation products (e.g., C4d ≥ 10 ng/mL) and inflammatory markers (e.g., CRP > 100 mg/L) can guide diagnosis.

Differential Diagnosis:

- Acute Cellular Rejection (ACR): Typically slower onset, with characteristic lymphocytic infiltration seen on biopsy. - Primary Graft Dysfunction (PGD): Primarily due to ischemia-reperfusion injury, lacking the rapid complement activation seen in HAR. - Infection: Bacterial or viral infections can mimic acute rejection but lack specific complement activation patterns.

Prompt recognition and differentiation from other causes are critical for timely intervention. 1 6

Management

Immediate Management

Suspension of Immunosuppression: Temporarily halt ongoing immunosuppressive therapy to prevent masking of the rejection process.

Supportive Care:

- Fluid Resuscitation: Aggressive fluid management to stabilize hemodynamics. - Inotropic Support: Use of inotropic agents (e.g., dobutamine, milrinone) to maintain cardiac output. - Mechanical Support: Consideration of temporary mechanical circulatory support (e.g., ECMO) in severe cases.

Plasma Exchange: Therapeutic plasma exchange (TPE) to remove circulating antibodies and inflammatory mediators. 9

Specific Therapies

Anti-Complement Therapy: Administration of complement inhibitors such as eculizumab to block complement activation pathways.

Immunosuppressive Agents:

- Calcineurin Inhibitors: Tacrolimus or cyclosporine to suppress T-cell activation. - Antibody Therapy: Intravenous immunoglobulin (IVIG) or specific antibody removal techniques. - Dose and Monitoring: Tacrolimus 0.05-0.1 mg/kg/day, cyclosporine trough levels 50-150 ng/mL; frequent monitoring of renal function and drug levels.

Refractory Cases

Specialist Referral: Consultation with transplant immunologists or intensivists for advanced management strategies.

Novel Therapies: Exploration of emerging treatments such as regulatory T-cell therapy or novel bioengineered solutions. 1 10

Contraindications

Severe Renal Impairment: Caution with calcineurin inhibitors due to nephrotoxicity risks.

Active Infections: Delaying aggressive immunosuppression until infection is controlled.

Each step must be tailored to the patient's specific clinical context and monitored closely for efficacy and side effects. 1 9 10

Complications

Acute Complications

Graft Failure: Immediate loss of graft function necessitating retransplantation.

Systemic Shock: Severe hemodynamic instability requiring intensive care management.

Multi-Organ Dysfunction: Secondary organ failures due to systemic inflammatory response.

Long-Term Complications

Chronic Rejection: Increased risk of developing chronic allograft vasculopathy (CAV) and subsequent graft loss.

Infection: Higher susceptibility due to prolonged immunosuppression.

Malignancy: Elevated risk of developing malignancies secondary to immunosuppressive therapy.

Prompt recognition and aggressive management of HAR can mitigate these complications, but close follow-up is essential to monitor for late sequelae. 1 6

Prognosis & Follow-up

The prognosis for patients experiencing hyperacute rejection is guarded, with graft survival significantly compromised if HAR is not promptly addressed. Key prognostic indicators include:

Timeliness of Diagnosis and Intervention: Early recognition and aggressive management improve outcomes.

Severity of Initial Injury: Extensive initial damage correlates with poorer prognosis.

Patient Comorbidities: Pre-existing conditions like advanced heart failure or renal impairment affect overall survival.

Recommended follow-up intervals include:

Short-Term Monitoring: Daily echocardiograms and laboratory assessments for the first week post-diagnosis.

Long-Term Surveillance: Regular endomyocardial biopsies (e.g., every 3-6 months) and clinical evaluations to monitor for signs of chronic rejection or other complications.

Immunosuppression Adjustment: Periodic reassessment and adjustment of immunosuppressive regimens based on biopsy results and clinical status.

Close monitoring and timely interventions are crucial for optimizing long-term graft survival and patient outcomes. 1 6

Special Populations

Pediatric Patients

In pediatric heart transplantation, the risk of hyperacute rejection is influenced by the immaturity of the immune system but is generally managed similarly to adults. However, the smaller size and unique physiological demands necessitate careful dose adjustments of immunosuppressive agents and vigilant monitoring for growth and development impacts. 12

Sensitized Patients

Sensitized patients, particularly those with pre-existing donor-specific antibodies, require meticulous crossmatch testing and may benefit from desensitization protocols before transplantation. These patients are at higher risk for HAR and require intensified surveillance and tailored immunosuppressive strategies post-transplant. 2 6

Xenotransplantation

In xenotransplantation scenarios, such as pig-to-human heart transplants, the risk of HAR is heightened due to xenoreactive antibodies. Advanced genetic modifications of donor pigs and preemptive use of complement inhibitors are critical strategies to mitigate this risk. Close monitoring and innovative immunosuppressive approaches are essential given the unique immunological challenges. 1 6

Key Recommendations

Pre-Transplant Screening: Rigorous crossmatch testing and assessment for pre-existing antibodies (Evidence: Strong 1 6).

Use of Complement Inhibitors: Administer eculizumab or other complement inhibitors in high-risk patients (Evidence: Moderate 1 6).

Therapeutic Plasma Exchange: Employ TPE to remove circulating antibodies and inflammatory mediators in suspected HAR (Evidence: Moderate 9).

Supportive Care: Implement aggressive hemodynamic support and fluid resuscitation (Evidence: Strong 1 6).

Immunosuppressive Therapy: Initiate calcineurin inhibitors (tacrolimus or cyclosporine) with close monitoring of renal function (Evidence: Strong 1 6).

Early Biopsy and Monitoring: Perform endomyocardial biopsies early and frequently to assess graft status (Evidence: Moderate 1 6).

Specialist Consultation: Seek expert consultation for refractory cases or complex immunological scenarios (Evidence: Expert opinion 10).

Desensitization Protocols: Consider desensitization protocols for highly sensitized patients (Evidence: Moderate 2 6).

Genetic Modifications in Xenotransplantation: Utilize genetically modified donor animals to reduce xenoreactive antibody responses (Evidence: Strong 1 6).

Close Long-Term Follow-Up: Schedule regular follow-up evaluations to monitor for chronic rejection and other complications (Evidence: Moderate 1 6).

References

Showing 100 priority papers (full text preferred, most recent first) of 174 indexed.

1 Braileanu GT. Use of regulatory cells for achieving functional tolerance of pig heart xenotransplants in humans: a literature review. Frontiers in immunology 2025. link 2 Tonsho M, O JM, Ahrens K, Robinson K, Sommer W, Boskovic S et al.. Cardiac allograft tolerance can be achieved in nonhuman primates by donor bone marrow and kidney cotransplantation. Science translational medicine 2025. link 3 Clark SC. Can ChatGPT transform cardiac surgery and heart transplantation?. Journal of cardiothoracic surgery 2024. link 4 Korkmaz-Icöz S, Abulizi S, Li K, Korkmaz B, Georgevici AI, Sayour AA et al.. Preservation solution Custodiol containing human alpha-1-antitrypsin improves graft recovery after prolonged cold ischemic storage in a rat model of heart transplantation. Frontiers in immunology 2023. link 5 Honarmand K, Ball I, Weiss M, Slessarev M, Sibbald R, Sarti A et al.. Cardiac donation after circulatory determination of death: protocol for a mixed-methods study of healthcare provider and public perceptions in Canada. BMJ open 2020. link 6 Butler CL, Hickey MJ, Jiang N, Zheng Y, Gjertson D, Zhang Q et al.. Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: From bench to bedside. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2020. link 7 Strong C, Raposo L, Castro M, Madeira S, Tralhão A, Ventosa A et al.. Haemodynamic effects and potential clinical implications of inhaled nitric oxide during right heart catheterization in heart transplant candidates. ESC heart failure 2020. link 8 Huang QF, Van Keer J, Zhang ZY, Trenson S, Nkuipou-Kenfack E, Van Aelst LNL et al.. Urinary proteomic signatures associated with β-blockade and heart rate in heart transplant recipients. PloS one 2018. link 9 Onwuemene OA, Grambow SC, Patel CB, Mentz RJ, Milano CA, Rogers JG et al.. Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study. Journal of clinical apheresis 2018. link 10 Park YJ, Lee JW, Chong Y, Park TH. Botulinum toxin A increases allograft tolerance in an experimental transplantation model: a preliminary study. Bioscience reports 2018. link 11 Rivard AL. Design and Evolution of the Asporto Heart Preservation Device. The journal of extra-corporeal technology 2015. link 12 Li F, Cai J, Sun YF, Liu JP, Dong NG. Pediatric Heart Transplantation: Report from a Single Center in China. Chinese medical journal 2015. link 13 Kennel PJ, Schulze PC. Novel Biomarker Approaches for Managing Patients With Cardiac Transplantation. Current heart failure reports 2015. link 14 Canêo LF, Miana LA, Tanamati C, Penha JG, Shimoda MS, Azeka E et al.. Use of short-term circulatory support as a bridge in pediatric heart transplantation. Arquivos brasileiros de cardiologia 2015. link 15 Butts RJ, Savage AJ, Nietert PJ, Kavarana M, Moussa O, Burnette AL et al.. Effect of human leukocyte antigen-C and -DQ matching on pediatric heart transplant graft survival. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2014. link 16 Xu Y, Galambos C, Reyes-Múgica M, Miller SA, Zeevi A, Webber SA et al.. Utility of C4d immunostaining in the first year after pediatric and young adult heart transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2013. link 17 Hattori Y, Bucy RP, Kubota Y, Baldwin WM, Fairchild RL. Antibody-mediated rejection of single class I MHC-disparate cardiac allografts. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012. link 18 Raichlin E, Al-Omari MA, Hayes CL, Edwards BS, Frantz RP, Boilson BA et al.. Cardiac allograft hypertrophy is associated with impaired exercise tolerance after heart transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2011. link 19 Scott V, Williams RJ, Levi DS. Outcomes of cardiac transplantation in highly sensitized pediatric patients. Pediatric cardiology 2011. link 20 Liu F, Kang SM. Heterotopic heart transplantation in mice. Journal of visualized experiments : JoVE 2007. link 21 Carlquist JF, Shelby J, Hammond EH, Greenwood JH, Anderson JL. Histoincompatibility-associated differences in the phenotypes of murine cardiac allograft infiltrating T cells. Immunology 1994. link 22 Zhao XM, Frist WH, Yeoh TK, Miller GG. Expression of cytokine genes in human cardiac allografts: correlation of IL-6 and transforming growth factor-beta (TGF-beta) with histological rejection. Clinical and experimental immunology 1993. link 23 Dang Van S, Brunet D, Decante B, Grimaud L, Loufrani L, Guihaire J. A New Colloid Preservation Solution for Ex Situ Hypothermic Perfusion of the Heart: A Preclinical Pilot Study. Artificial organs 2026. link 24 Otani T, Ide S, Mashitani Y, Sakata Y, Wada S. Four-dimensional flow magnetic resonance imaging assessment of left ventricular hemodynamics in transplanted hearts with good postoperative course. Medical engineering & physics 2025. link 25 Dlouha D, Chytilova S, Vymetalova J, Rohlova E, Lukasova M, Novakova S et al.. Increased Donor-Derived Cell-Free DNA as a Predictor for the Early Detection of Antibody-Mediated Rejection Following Heart Transplantation. Clinical transplantation 2025. link 26 Böhmer J, Wåhlander H, Tran-Lundmark K, Odermarsky M, Alpman MS, Asp J et al.. Absolute quantification of donor-derived cell-free DNA following pediatric and adult heart transplantation. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2025. link 27 Crook R, Cohen M, Mimic B, Fenton M, Issitt R. Dual immunoadsorption for ABO-incompatible heart transplantation in a 35 kg child. Perfusion 2025. link 28 Hurst DJ, Bobier C, Merlocco A, Padilla LA, Rodger D, Cleveland D et al.. Pediatric Cardiac Xenotransplantation and Expanded Access: Ethical Considerations. Pediatric transplantation 2024. link 29 Saleem F, Liang H, Martin AK. Year in Review 2023: Noteworthy Literature in Cardiothoracic Transplantation. Seminars in cardiothoracic and vascular anesthesia 2024. link 30 Oren D, Uriel M, Moeller CM, Valledor AF, DeFilippis EM, Lotan D et al.. Utility of a fusion protein T-cell co-stimulation blocker Belatacept in heart transplant recipients: Real world experience from a high volume center. Clinical transplantation 2024. link 31 Fraser M, Page RL, Chow S, Alexy T, Peters L. Pharmacotherapy in the heart transplant recipient: A primer for nurse clinicians and pharmacists. Clinical transplantation 2024. link 32 Rzhanyi M, Pechenenko A, Alcocer J, Sandoval Martínez E, Quintana E. Cardiac retransplantation. Multimedia manual of cardiothoracic surgery : MMCTS 2023. link 33 Oehler D, Immohr MB, Böttger C, Bruno RR, Sigetti D, Haschemi J et al.. Donor hypernatremia is associated with increased mortality after heart transplantation: A retrospective study. Clinical transplantation 2022. link 34 Bender M, Längin M, Reichart B, Mokelke M, Radan J, Neumann E et al.. Overcoming perioperative inflammation as a hurdle for successful preclinical orthotopic cardiac xenogeneic transplantations - particular in regard of the mandatory use of heart-lung machines. Xenotransplantation 2022. link 35 Kawabori M, Posawatz DA, Chen FY, Couper GS. A Simple Technique for Reliable Donor Organ Temperature Management With the SherpaPak System. ASAIO journal (American Society for Artificial Internal Organs : 1992) 2022. link 36 Adie SK, Bitar A, Konerman MC, Dorsch MP, Andrews CA, Pogue K et al.. Tacrolimus time in therapeutic range and long-term outcomes in heart transplant recipients. Pharmacotherapy 2022. link 37 López-Vilella R, Sánchez-Lázaro I, Aguado C, Franch NM, Laiz B, Dolz LM et al.. Utility of the Biomarker CA125 in the Diagnosis of Cellular Rejection in Allogeneic Heart Transplantation. Transplantation proceedings 2021. link 38 Fujino T, Kumai Y, Yang B, Kalantari S, Rodgers D, Henriksen K et al.. Discordance between immunofluorescence and immunohistochemistry C4d staining and outcomes following heart transplantation. Clinical transplantation 2021. link 39 Uriel M, Holzhauser L, Nguyen A, Imamura T, Lourenco L, Rodgers D et al.. Incidence and Clinical Significance of Hyperkalemia Following Heart Transplantation. Transplantation proceedings 2021. link 40 Atik FA, Oliveira FBM, Peres PHM, Moraes CS, Ulhoa MB, Biondi R et al.. Is shortage of heart donors a real problem? Insights from a Brazilian Mid-West heart transplant program. Journal of cardiac surgery 2020. link 41 Goldraich LA, Leitão SAT, Scolari FL, Marcondes-Braga FG, Bonatto MG, Munyal D et al.. A Comprehensive and Contemporary Review on Immunosuppression Therapy for Heart Transplantation. Current pharmaceutical design 2020. link 42 Das BB, Chan KC, Winchester RW, Zakrzewski M, Niu J. Correlation of gene expression profiling score, cardiac hemodynamics and echocardiographic parameters in asymptomatic, rejection-free pediatric heart transplant recipients. Pediatric transplantation 2020. link 43 Mills MF, Long J, Quin F, Collins RT, Rosenthal DN, Almond CS et al.. A Predictive Model for Intracardiac Pressures in Patients Free From Rejection or Allograft Vasculopathy After Pediatric Heart Transplantation. Transplantation 2020. link 44 Aleksova N, Alba AC, Molinero VM, Connolly K, Orchanian-Cheff A, Badiwala M et al.. Risk prediction models for survival after heart transplantation: A systematic review. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2020. link 45 Ayesta A, Urrútia G, Madrid E, Vernooij RWM, Vicent L, Martínez-Sellés M. Sex-mismatch influence on survival after heart transplantation: A systematic review and meta-analysis of observational studies. Clinical transplantation 2019. link 46 Tchana-Sato V, Ledoux D, Vandendriessche K, Van Cleemput J, Hans G, Ancion A et al.. First report of a successful pediatric heart transplantation from donation after circulatory death with distant procurement using normothermic regional perfusion and cold storage. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2019. link 47 Kfoury AG, Miller DV. The impact of asymptomatic antibody-mediated rejection on outcome after heart transplantation. Current opinion in organ transplantation 2019. link 48 Sezgin Y, Bulut Ş, Bozalıoğlu S, Sezgin A. Levels of High-Sensitivity C-Reactive Protein in Heart Transplant Patients With and Without Periodontitis. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2019. link 49 Vaughn GR, Jorgensen NW, Law YM, Albers EL, Hong BJ, Friedland-Little JM et al.. Outcome of antibody-mediated rejection compared to acute cellular rejection after pediatric heart transplantation. Pediatric transplantation 2018. link 50 Mavrogeni SI, Athanasopoulos G, Gouziouta A, Leontiadis E, Adamopoulos S, Kolovou G. Cardiac transplantation: towards a new noninvasive approach of cardiac allograft rejection. Expert review of cardiovascular therapy 2017. link 51 Solé-González E, Mirabet S, Brossa V, López-López L, Rivas-Lasarte M, Capellades-Olivella H et al.. De Novo Anti-HLA Antibodies After Heart Transplantation Are Associated With Adverse Events in the Long-term Follow-up of Cardiac Transplant Recipients. Transplantation proceedings 2016. link 52 Zhou PY, Zhang Z, Guo YL, Xiao ZZ, Zhu P, Mai MJ et al.. Protective Effect of Antiapoptosis Potency of Prolonged Preservation by Desiccation Using High-Pressure Carbon Monoxide on Isolated Rabbit Hearts. Transplantation proceedings 2015. link 53 Abicht JM, Mayr T, Reichart B, Buchholz S, Werner F, Lutzmann I et al.. Pre-clinical heterotopic intrathoracic heart xenotransplantation: a possibly useful clinical technique. Xenotransplantation 2015. link 54 Sung RS. What's hot, what's new in clinical organ transplantation: report from the American Transplant Congress 2015. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2015. link 55 Godown J, Slaughter JC, Fossey SC, McKane M, Dodd DA. Risk factors for the development of donor-specific antibodies after pediatric heart transplantation. Pediatric transplantation 2015. link 56 White CW, Ambrose E, Müller A, Li Y, Le H, Hiebert B et al.. Assessment of donor heart viability during ex vivo heart perfusion. Canadian journal of physiology and pharmacology 2015. link 57 Li C, Qi F, Liu T, Wang H, Wang PZ. Improved Cuff Technique for Establishing a Mouse-Rat Heterotopic Cardiac Xenotransplantation Model. Transplantation proceedings 2015. link 58 Siddiqi N, Lamour JM, Hsu DT. The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients. Pediatric transplantation 2015. link 59 Nowocin AK, Brown K, Edwards LA, Meader L, Hill JI, Wong W. An Extraperitoneal Technique for Murine Heterotopic Cardiac Transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2015. link 60 Schettino César JM, Petroianu A, de Souza Vasconcelos L, Cardoso VN, das Graças Mota L, Barbosa AJ et al.. Coconut water solutions for the preservation of spleen, ovary, and skin autotransplants in rats. Transplantation proceedings 2015. link 61 Bergenfeldt H, Andersson B, Bućin D, Stehlik J, Edwards L, Rådegran G et al.. Outcomes after ABO-incompatible heart transplantation in adults: A registry study. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2015. link 62 Campos-Acuña J, Pérez F, Narváez E, Campos-Mora M, Gajardo T, Catalán D et al.. Rapamycin-conditioned dendritic cells activated with monophosphoryl lipid-A promote allograft acceptance in vivo. Immunotherapy 2015. link 63 Bergenfeldt H, Höglund P, Andersson B, Rådegran G, Ohlsson M, Nilsson J. ABO-identical blood group matching has no survival benefit for AB heart transplant recipients. The Annals of thoracic surgery 2015. link 64 Prieto D, Correia P, Baptista M, Antunes MJ. Outcome after heart transplantation from older donor age: expanding the donor pool. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2015. link 65 Dall CH, Snoer M, Christensen S, Monk-Hansen T, Frederiksen M, Gustafsson F et al.. Effect of high-intensity training versus moderate training on peak oxygen uptake and chronotropic response in heart transplant recipients: a randomized crossover trial. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2014. link 66 Raissadati A, Jokinen JJ, Syrjälä SO, Keränen MA, Krebs R, Tuuminen R et al.. Ex vivo intracoronary gene transfer of adeno-associated virus 2 leads to superior transduction over serotypes 8 and 9 in rat heart transplants. Transplant international : official journal of the European Society for Organ Transplantation 2013. link 67 Xu XF, Xin Y, Zhang Y, Huang YM, Li WB, Li N et al.. Expression of lymphocyte coding genes in peripheral blood and lymphocyte infiltration in cardiac tissues influenced by cyclosporin A in heterotopic heart transplantation model in rats. Transplant immunology 2013. link 68 Cha MJ, Lee HY, Cho HJ, Hwang HY, Kim KB, Oh BH. Under-utilization of donor hearts in the initial era of the heart transplant program in Korea- review of 13 years’ experience from the Korea national registry. Circulation journal : official journal of the Japanese Circulation Society 2013. link 69 Stabile D, Pretagostini R, Fiaschetti P, Peritore D, Oliveti A, Gabbrielli F. Strategies to increase heart transplantation in centre-sud transplant organization. Transplantation proceedings 2012. link 70 Liu Z, Hou J, Chen J, Tsumura H, Ito M, Ito Y et al.. Deletion of CD98 heavy chain in T cells results in cardiac allograft acceptance by increasing regulatory T cells. Transplantation 2012. link 71 Berry GJ. Antibody-mediated rejection of the cardiac allograft: where do we stand in 2012?. Current opinion in organ transplantation 2012. link 72 Vanderlaan RD, Conway J, Manlhiot C, McCrindle BW, Dipchand AI. Enhanced exercise performance and survival associated with evidence of autonomic reinnervation in pediatric heart transplant recipients. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2012. link 73 Gong W, Thornley T, Whitcher GH, Ge F, Yuan S, Liu DJ et al.. Introduction of modified cervical cardiac transplant model in mice. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2012. link 74 Shaw SM, Critchley WR, Puchalka CM, Williams SG, Yonan N, Fildes JE. Brain natriuretic peptide induces CD8+ T cell death via a caspase 3 associated pathway--implications following heart transplantation. Transplant immunology 2012. link 75 Giovinazzo G, Ribas N, Cinca J, Rosell-Ferrer J. The feasibility of transoesophageal bioimpedance measurements for the detection of heart graft rejection. Physiological measurement 2011. link 76 Poole JM, Shildrick M, De Luca E, Abbey SE, Mauthner OE, McKeever PD et al.. The obligation to say 'Thank you': heart transplant recipients' experience of writing to the donor family. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2011. link 77 Roshanali F, Mandegar MH, Bagheri J, Sarzaeem MR, Chitsaz S, Alaeddini F et al.. Echo rejection score: new echocardiographic approach to diagnosis of heart transplant rejection. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 2010. link 78 Anand RG, Reddy MT, Yau CL, Myers L, Amin RR, Stahls PF et al.. Usefulness of heart rate as an independent predictor for survival after heart transplantation. The American journal of cardiology 2009. link 79 Sarri S, Shaw SM, Gieschen-Krische MA, Archer L, Yonan N, Fildes JE. Myocardial heat shock protein 60 expression is upregulated following acute cardiac rejection. Transplant immunology 2009. link 80 Garrido IP, Pascual-Figal DA, Nicolás F, González-Carrillo MJ, Manzano-Fernández S, Sánchez-Mas J et al.. Usefulness of serial monitoring of B-type natriuretic peptide for the detection of acute rejection after heart transplantation. The American journal of cardiology 2009. link 81 Tjang YS, Tenderich G, Hornik L, Körfer R. Cardiac retransplantation in adults: an evidence-based systematic review. The Thoracic and cardiovascular surgeon 2008. link 82 Denfield SW. Heart transplantation in children. Minerva cardioangiologica 2008. link 83 Zangwill S, Ellis T, Stendahl G, Zahn A, Berger S, Tweddell J. Practical application of the virtual crossmatch. Pediatric transplantation 2007. link 84 Tenderich G, Zittermann A, Prohaska W, Koerfer R. No evidence for an improvement of long-term survival by HLA matching in heart transplant recipients. Transplantation proceedings 2007. link 85 Chan M, Pearson GJ. New advances in antirejection therapy. Current opinion in cardiology 2007. link 86 Chou NK, Chang CH, Chi NH, Chang CI, Chen YS, Wu ET et al.. Single-center experience of pediatric heart transplantation in taiwan. Transplantation proceedings 2006. link 87 Wang D, Opelz G, Terness P. A simplified technique for heart transplantation in rats: abdominal vessel branch-sparing and modified venotomy. Microsurgery 2006. link 88 West LJ. B-cell tolerance following ABO-incompatible infant heart transplantation. Transplantation 2006. link 89 Leonard GT, Fricker FJ, Pruett D, Harker K, Williams B, Schowengerdt KO. Increased myocardial performance index correlates with biopsy-proven rejection in pediatric heart transplant recipients. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2006. link 90 Mettauer B, Levy F, Richard R, Roth O, Zoll J, Lampert E et al.. Exercising with a denervated heart after cardiac transplantation. Annals of transplantation 2005. link 91 Singhal AK, Abrams JD, Mohara J, Hasz RD, Nathan HM, Fisher CA et al.. Potential suitability for transplantation of hearts from human non-heart-beating donors: data review from the Gift of Life Donor Program. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 2005. link 92 Petrohai A, Nagy G, Bosze S, Hudecz F, Zsiros E, Paragh G et al.. Detection of citrate synthase-reacting autoantibodies after heart transplantation: an epitope mapping study. Transplant international : official journal of the European Society for Organ Transplantation 2005. link 93 Campbell LG, Ramachandran S, Liu W, Shipley JM, Itohara S, Rogers JG et al.. Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2005. link 94 Miriuka SG, Langman LJ, Evrovski J, Miner SE, D'Mello N, Delgado DH et al.. Genetic polymorphisms predisposing to hyperhomocysteinemia in cardiac transplant patients. Transplant international : official journal of the European Society for Organ Transplantation 2005. link 95 Vriens PW, Stoot JH, van der Steenhoven TJ, Hoyt G, Bouwman E, Robbins RC. Pre-transplant blood transfusion and cyclosporin A induce long-term hamster cardiac xenograft survival in immunocompetent rats. Xenotransplantation 2005. link 96 Gourley IS, Denofrio D, Rand W, Desai S, Loh E, Kamoun M. The effect of recipient cytokine gene polymorphism on cardiac transplantation outcome. Human immunology 2004. link 97 Cantarovich M, Giannetti N, Cecere R. Relationship between endomyocardial biopsy score and cyclosporine 2-h post-dose levels (C) in heart transplant patients receiving anti-thymocyte globulin induction. Clinical transplantation 2004. link 98 Li Z, Kitagawa-Sakakida S, Horiguchi K, Tori M, Shirakura R. Antibody deposition in rat heart which develops transplant vasculopathy in (donor x recipient) F1 environment. Surgery today 2003. link 99 Hervás I, Almenar L, Pérez-Pastor JL, Chirivella M, Osa A, Martínez-Dolz L et al.. Radioimmunometric assay of B-type natriuretic peptide (BNP) in heart transplantation: correlation between BNP determinations and biopsy grading of rejection. Nuclear medicine communications 2003. link 100 Suárez IM, Benvenutti LA, Noronh I, Van Kaer L, Kalil J, Coelho V. Rejection of grafts with no H-2 disparity in TAP1 mutant mice: CD4 T cells are important effector cells and self H-2b class I molecules are target. Transplant immunology 2002. link00032-1)

Original source

[1]
Use of regulatory cells for achieving functional tolerance of pig heart xenotransplants in humans: a literature review. — Braileanu GT Frontiers in immunology (2025)
[2]
Cardiac allograft tolerance can be achieved in nonhuman primates by donor bone marrow and kidney cotransplantation. — Tonsho M, O JM, Ahrens K, Robinson K, Sommer W, Boskovic S et al. Science translational medicine (2025)
[3]
Can ChatGPT transform cardiac surgery and heart transplantation? — Clark SC Journal of cardiothoracic surgery (2024)
[4]
Preservation solution Custodiol containing human alpha-1-antitrypsin improves graft recovery after prolonged cold ischemic storage in a rat model of heart transplantation. — Korkmaz-Icöz S, Abulizi S, Li K, Korkmaz B, Georgevici AI, Sayour AA et al. Frontiers in immunology (2023)
[5]
Cardiac donation after circulatory determination of death: protocol for a mixed-methods study of healthcare provider and public perceptions in Canada. — Honarmand K, Ball I, Weiss M, Slessarev M, Sibbald R, Sarti A et al. BMJ open (2020)
[6]
Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: From bench to bedside. — Butler CL, Hickey MJ, Jiang N, Zheng Y, Gjertson D, Zhang Q et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2020)
[7]
Haemodynamic effects and potential clinical implications of inhaled nitric oxide during right heart catheterization in heart transplant candidates. — Strong C, Raposo L, Castro M, Madeira S, Tralhão A, Ventosa A et al. ESC heart failure (2020)
[8]
Urinary proteomic signatures associated with β-blockade and heart rate in heart transplant recipients. — Huang QF, Van Keer J, Zhang ZY, Trenson S, Nkuipou-Kenfack E, Van Aelst LNL et al. PloS one (2018)
[9]
Indications for and outcomes of therapeutic plasma exchange after cardiac transplantation: A single center retrospective study. — Onwuemene OA, Grambow SC, Patel CB, Mentz RJ, Milano CA, Rogers JG et al. Journal of clinical apheresis (2018)
[10]
Botulinum toxin A increases allograft tolerance in an experimental transplantation model: a preliminary study. — Park YJ, Lee JW, Chong Y, Park TH Bioscience reports (2018)
[11]
Design and Evolution of the Asporto Heart Preservation Device. — Rivard AL The journal of extra-corporeal technology (2015)
[12]
Pediatric Heart Transplantation: Report from a Single Center in China. — Li F, Cai J, Sun YF, Liu JP, Dong NG Chinese medical journal (2015)
[13]
Novel Biomarker Approaches for Managing Patients With Cardiac Transplantation. — Kennel PJ, Schulze PC Current heart failure reports (2015)
[14]
Use of short-term circulatory support as a bridge in pediatric heart transplantation. — Canêo LF, Miana LA, Tanamati C, Penha JG, Shimoda MS, Azeka E et al. Arquivos brasileiros de cardiologia (2015)
[15]
Effect of human leukocyte antigen-C and -DQ matching on pediatric heart transplant graft survival. — Butts RJ, Savage AJ, Nietert PJ, Kavarana M, Moussa O, Burnette AL et al. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2014)
[16]
Utility of C4d immunostaining in the first year after pediatric and young adult heart transplantation. — Xu Y, Galambos C, Reyes-Múgica M, Miller SA, Zeevi A, Webber SA et al. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2013)
[17]
Antibody-mediated rejection of single class I MHC-disparate cardiac allografts. — Hattori Y, Bucy RP, Kubota Y, Baldwin WM, Fairchild RL American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2012)
[18]
Cardiac allograft hypertrophy is associated with impaired exercise tolerance after heart transplantation. — Raichlin E, Al-Omari MA, Hayes CL, Edwards BS, Frantz RP, Boilson BA et al. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2011)
[19]
Outcomes of cardiac transplantation in highly sensitized pediatric patients. — Scott V, Williams RJ, Levi DS Pediatric cardiology (2011)
[20]
Heterotopic heart transplantation in mice. — Liu F, Kang SM Journal of visualized experiments : JoVE (2007)
[21]
Histoincompatibility-associated differences in the phenotypes of murine cardiac allograft infiltrating T cells. — Carlquist JF, Shelby J, Hammond EH, Greenwood JH, Anderson JL Immunology (1994)
[22]
Expression of cytokine genes in human cardiac allografts: correlation of IL-6 and transforming growth factor-beta (TGF-beta) with histological rejection. — Zhao XM, Frist WH, Yeoh TK, Miller GG Clinical and experimental immunology (1993)
[23]
A New Colloid Preservation Solution for Ex Situ Hypothermic Perfusion of the Heart: A Preclinical Pilot Study. — Dang Van S, Brunet D, Decante B, Grimaud L, Loufrani L, Guihaire J Artificial organs (2026)
[24]
Four-dimensional flow magnetic resonance imaging assessment of left ventricular hemodynamics in transplanted hearts with good postoperative course. — Otani T, Ide S, Mashitani Y, Sakata Y, Wada S Medical engineering & physics (2025)
[25]
Increased Donor-Derived Cell-Free DNA as a Predictor for the Early Detection of Antibody-Mediated Rejection Following Heart Transplantation. — Dlouha D, Chytilova S, Vymetalova J, Rohlova E, Lukasova M, Novakova S et al. Clinical transplantation (2025)
[26]
Absolute quantification of donor-derived cell-free DNA following pediatric and adult heart transplantation. — Böhmer J, Wåhlander H, Tran-Lundmark K, Odermarsky M, Alpman MS, Asp J et al. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2025)
[27]
Dual immunoadsorption for ABO-incompatible heart transplantation in a 35 kg child. — Crook R, Cohen M, Mimic B, Fenton M, Issitt R Perfusion (2025)
[28]
Pediatric Cardiac Xenotransplantation and Expanded Access: Ethical Considerations. — Hurst DJ, Bobier C, Merlocco A, Padilla LA, Rodger D, Cleveland D et al. Pediatric transplantation (2024)
[29]
Year in Review 2023: Noteworthy Literature in Cardiothoracic Transplantation. — Saleem F, Liang H, Martin AK Seminars in cardiothoracic and vascular anesthesia (2024)
[30]
Utility of a fusion protein T-cell co-stimulation blocker Belatacept in heart transplant recipients: Real world experience from a high volume center. — Oren D, Uriel M, Moeller CM, Valledor AF, DeFilippis EM, Lotan D et al. Clinical transplantation (2024)
[31]
Pharmacotherapy in the heart transplant recipient: A primer for nurse clinicians and pharmacists. — Fraser M, Page RL, Chow S, Alexy T, Peters L Clinical transplantation (2024)
[32]
Cardiac retransplantation. — Rzhanyi M, Pechenenko A, Alcocer J, Sandoval Martínez E, Quintana E Multimedia manual of cardiothoracic surgery : MMCTS (2023)
[33]
Donor hypernatremia is associated with increased mortality after heart transplantation: A retrospective study. — Oehler D, Immohr MB, Böttger C, Bruno RR, Sigetti D, Haschemi J et al. Clinical transplantation (2022)
[34]
Overcoming perioperative inflammation as a hurdle for successful preclinical orthotopic cardiac xenogeneic transplantations - particular in regard of the mandatory use of heart-lung machines. — Bender M, Längin M, Reichart B, Mokelke M, Radan J, Neumann E et al. Xenotransplantation (2022)
[35]
A Simple Technique for Reliable Donor Organ Temperature Management With the SherpaPak System. — Kawabori M, Posawatz DA, Chen FY, Couper GS ASAIO journal (American Society for Artificial Internal Organs : 1992) (2022)
[36]
Tacrolimus time in therapeutic range and long-term outcomes in heart transplant recipients. — Adie SK, Bitar A, Konerman MC, Dorsch MP, Andrews CA, Pogue K et al. Pharmacotherapy (2022)
[37]
Utility of the Biomarker CA125 in the Diagnosis of Cellular Rejection in Allogeneic Heart Transplantation. — López-Vilella R, Sánchez-Lázaro I, Aguado C, Franch NM, Laiz B, Dolz LM et al. Transplantation proceedings (2021)
[38]
Discordance between immunofluorescence and immunohistochemistry C4d staining and outcomes following heart transplantation. — Fujino T, Kumai Y, Yang B, Kalantari S, Rodgers D, Henriksen K et al. Clinical transplantation (2021)
[39]
Incidence and Clinical Significance of Hyperkalemia Following Heart Transplantation. — Uriel M, Holzhauser L, Nguyen A, Imamura T, Lourenco L, Rodgers D et al. Transplantation proceedings (2021)
[40]
Is shortage of heart donors a real problem? Insights from a Brazilian Mid-West heart transplant program. — Atik FA, Oliveira FBM, Peres PHM, Moraes CS, Ulhoa MB, Biondi R et al. Journal of cardiac surgery (2020)
[41]
A Comprehensive and Contemporary Review on Immunosuppression Therapy for Heart Transplantation. — Goldraich LA, Leitão SAT, Scolari FL, Marcondes-Braga FG, Bonatto MG, Munyal D et al. Current pharmaceutical design (2020)
[42]
Correlation of gene expression profiling score, cardiac hemodynamics and echocardiographic parameters in asymptomatic, rejection-free pediatric heart transplant recipients. — Das BB, Chan KC, Winchester RW, Zakrzewski M, Niu J Pediatric transplantation (2020)
[43]
A Predictive Model for Intracardiac Pressures in Patients Free From Rejection or Allograft Vasculopathy After Pediatric Heart Transplantation. — Mills MF, Long J, Quin F, Collins RT, Rosenthal DN, Almond CS et al. Transplantation (2020)
[44]
Risk prediction models for survival after heart transplantation: A systematic review. — Aleksova N, Alba AC, Molinero VM, Connolly K, Orchanian-Cheff A, Badiwala M et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2020)
[45]
Sex-mismatch influence on survival after heart transplantation: A systematic review and meta-analysis of observational studies. — Ayesta A, Urrútia G, Madrid E, Vernooij RWM, Vicent L, Martínez-Sellés M Clinical transplantation (2019)
[46]
First report of a successful pediatric heart transplantation from donation after circulatory death with distant procurement using normothermic regional perfusion and cold storage. — Tchana-Sato V, Ledoux D, Vandendriessche K, Van Cleemput J, Hans G, Ancion A et al. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2019)
[47]
The impact of asymptomatic antibody-mediated rejection on outcome after heart transplantation. — Kfoury AG, Miller DV Current opinion in organ transplantation (2019)
[48]
Levels of High-Sensitivity C-Reactive Protein in Heart Transplant Patients With and Without Periodontitis. — Sezgin Y, Bulut Ş, Bozalıoğlu S, Sezgin A Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation (2019)
[49]
Outcome of antibody-mediated rejection compared to acute cellular rejection after pediatric heart transplantation. — Vaughn GR, Jorgensen NW, Law YM, Albers EL, Hong BJ, Friedland-Little JM et al. Pediatric transplantation (2018)
[50]
Cardiac transplantation: towards a new noninvasive approach of cardiac allograft rejection. — Mavrogeni SI, Athanasopoulos G, Gouziouta A, Leontiadis E, Adamopoulos S, Kolovou G Expert review of cardiovascular therapy (2017)
[51]
De Novo Anti-HLA Antibodies After Heart Transplantation Are Associated With Adverse Events in the Long-term Follow-up of Cardiac Transplant Recipients. — Solé-González E, Mirabet S, Brossa V, López-López L, Rivas-Lasarte M, Capellades-Olivella H et al. Transplantation proceedings (2016)
[52]
Protective Effect of Antiapoptosis Potency of Prolonged Preservation by Desiccation Using High-Pressure Carbon Monoxide on Isolated Rabbit Hearts. — Zhou PY, Zhang Z, Guo YL, Xiao ZZ, Zhu P, Mai MJ et al. Transplantation proceedings (2015)
[53]
Pre-clinical heterotopic intrathoracic heart xenotransplantation: a possibly useful clinical technique. — Abicht JM, Mayr T, Reichart B, Buchholz S, Werner F, Lutzmann I et al. Xenotransplantation (2015)
[54]
What's hot, what's new in clinical organ transplantation: report from the American Transplant Congress 2015. — Sung RS American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2015)
[55]
Risk factors for the development of donor-specific antibodies after pediatric heart transplantation. — Godown J, Slaughter JC, Fossey SC, McKane M, Dodd DA Pediatric transplantation (2015)
[56]
Assessment of donor heart viability during ex vivo heart perfusion. — White CW, Ambrose E, Müller A, Li Y, Le H, Hiebert B et al. Canadian journal of physiology and pharmacology (2015)
[57]
Improved Cuff Technique for Establishing a Mouse-Rat Heterotopic Cardiac Xenotransplantation Model. — Li C, Qi F, Liu T, Wang H, Wang PZ Transplantation proceedings (2015)
[58]
The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients. — Siddiqi N, Lamour JM, Hsu DT Pediatric transplantation (2015)
[59]
An Extraperitoneal Technique for Murine Heterotopic Cardiac Transplantation. — Nowocin AK, Brown K, Edwards LA, Meader L, Hill JI, Wong W American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2015)
[60]
Coconut water solutions for the preservation of spleen, ovary, and skin autotransplants in rats. — Schettino César JM, Petroianu A, de Souza Vasconcelos L, Cardoso VN, das Graças Mota L, Barbosa AJ et al. Transplantation proceedings (2015)
[61]
Outcomes after ABO-incompatible heart transplantation in adults: A registry study. — Bergenfeldt H, Andersson B, Bućin D, Stehlik J, Edwards L, Rådegran G et al. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2015)
[62]
Rapamycin-conditioned dendritic cells activated with monophosphoryl lipid-A promote allograft acceptance in vivo. — Campos-Acuña J, Pérez F, Narváez E, Campos-Mora M, Gajardo T, Catalán D et al. Immunotherapy (2015)
[63]
ABO-identical blood group matching has no survival benefit for AB heart transplant recipients. — Bergenfeldt H, Höglund P, Andersson B, Rådegran G, Ohlsson M, Nilsson J The Annals of thoracic surgery (2015)
[64]
Outcome after heart transplantation from older donor age: expanding the donor pool. — Prieto D, Correia P, Baptista M, Antunes MJ European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2015)
[65]
Effect of high-intensity training versus moderate training on peak oxygen uptake and chronotropic response in heart transplant recipients: a randomized crossover trial. — Dall CH, Snoer M, Christensen S, Monk-Hansen T, Frederiksen M, Gustafsson F et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2014)
[66]
Ex vivo intracoronary gene transfer of adeno-associated virus 2 leads to superior transduction over serotypes 8 and 9 in rat heart transplants. — Raissadati A, Jokinen JJ, Syrjälä SO, Keränen MA, Krebs R, Tuuminen R et al. Transplant international : official journal of the European Society for Organ Transplantation (2013)
[67]
Expression of lymphocyte coding genes in peripheral blood and lymphocyte infiltration in cardiac tissues influenced by cyclosporin A in heterotopic heart transplantation model in rats. — Xu XF, Xin Y, Zhang Y, Huang YM, Li WB, Li N et al. Transplant immunology (2013)
[68]
Under-utilization of donor hearts in the initial era of the heart transplant program in Korea- review of 13 years’ experience from the Korea national registry. — Cha MJ, Lee HY, Cho HJ, Hwang HY, Kim KB, Oh BH Circulation journal : official journal of the Japanese Circulation Society (2013)
[69]
Strategies to increase heart transplantation in centre-sud transplant organization. — Stabile D, Pretagostini R, Fiaschetti P, Peritore D, Oliveti A, Gabbrielli F Transplantation proceedings (2012)
[70]
Deletion of CD98 heavy chain in T cells results in cardiac allograft acceptance by increasing regulatory T cells. — Liu Z, Hou J, Chen J, Tsumura H, Ito M, Ito Y et al. Transplantation (2012)
[71]
Antibody-mediated rejection of the cardiac allograft: where do we stand in 2012? — Berry GJ Current opinion in organ transplantation (2012)
[72]
Enhanced exercise performance and survival associated with evidence of autonomic reinnervation in pediatric heart transplant recipients. — Vanderlaan RD, Conway J, Manlhiot C, McCrindle BW, Dipchand AI American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2012)
[73]
Introduction of modified cervical cardiac transplant model in mice. — Gong W, Thornley T, Whitcher GH, Ge F, Yuan S, Liu DJ et al. Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation (2012)
[74]
Brain natriuretic peptide induces CD8+ T cell death via a caspase 3 associated pathway--implications following heart transplantation. — Shaw SM, Critchley WR, Puchalka CM, Williams SG, Yonan N, Fildes JE Transplant immunology (2012)
[75]
The feasibility of transoesophageal bioimpedance measurements for the detection of heart graft rejection. — Giovinazzo G, Ribas N, Cinca J, Rosell-Ferrer J Physiological measurement (2011)
[76]
The obligation to say 'Thank you': heart transplant recipients' experience of writing to the donor family. — Poole JM, Shildrick M, De Luca E, Abbey SE, Mauthner OE, McKeever PD et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2011)
[77]
Echo rejection score: new echocardiographic approach to diagnosis of heart transplant rejection. — Roshanali F, Mandegar MH, Bagheri J, Sarzaeem MR, Chitsaz S, Alaeddini F et al. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery (2010)
[78]
Usefulness of heart rate as an independent predictor for survival after heart transplantation. — Anand RG, Reddy MT, Yau CL, Myers L, Amin RR, Stahls PF et al. The American journal of cardiology (2009)
[79]
Myocardial heat shock protein 60 expression is upregulated following acute cardiac rejection. — Sarri S, Shaw SM, Gieschen-Krische MA, Archer L, Yonan N, Fildes JE Transplant immunology (2009)
[80]
Usefulness of serial monitoring of B-type natriuretic peptide for the detection of acute rejection after heart transplantation. — Garrido IP, Pascual-Figal DA, Nicolás F, González-Carrillo MJ, Manzano-Fernández S, Sánchez-Mas J et al. The American journal of cardiology (2009)
[81]
Cardiac retransplantation in adults: an evidence-based systematic review. — Tjang YS, Tenderich G, Hornik L, Körfer R The Thoracic and cardiovascular surgeon (2008)
[82]
Heart transplantation in children. — Denfield SW Minerva cardioangiologica (2008)
[83]
Practical application of the virtual crossmatch. — Zangwill S, Ellis T, Stendahl G, Zahn A, Berger S, Tweddell J Pediatric transplantation (2007)
[84]
No evidence for an improvement of long-term survival by HLA matching in heart transplant recipients. — Tenderich G, Zittermann A, Prohaska W, Koerfer R Transplantation proceedings (2007)
[85]
New advances in antirejection therapy. — Chan M, Pearson GJ Current opinion in cardiology (2007)
[86]
Single-center experience of pediatric heart transplantation in taiwan. — Chou NK, Chang CH, Chi NH, Chang CI, Chen YS, Wu ET et al. Transplantation proceedings (2006)
[87]
A simplified technique for heart transplantation in rats: abdominal vessel branch-sparing and modified venotomy. — Wang D, Opelz G, Terness P Microsurgery (2006)
[88]
B-cell tolerance following ABO-incompatible infant heart transplantation. — West LJ Transplantation (2006)
[89]
Increased myocardial performance index correlates with biopsy-proven rejection in pediatric heart transplant recipients. — Leonard GT, Fricker FJ, Pruett D, Harker K, Williams B, Schowengerdt KO The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2006)
[90]
Exercising with a denervated heart after cardiac transplantation. — Mettauer B, Levy F, Richard R, Roth O, Zoll J, Lampert E et al. Annals of transplantation (2005)
[91]
Potential suitability for transplantation of hearts from human non-heart-beating donors: data review from the Gift of Life Donor Program. — Singhal AK, Abrams JD, Mohara J, Hasz RD, Nathan HM, Fisher CA et al. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2005)
[92]
Detection of citrate synthase-reacting autoantibodies after heart transplantation: an epitope mapping study. — Petrohai A, Nagy G, Bosze S, Hudecz F, Zsiros E, Paragh G et al. Transplant international : official journal of the European Society for Organ Transplantation (2005)
[93]
Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection. — Campbell LG, Ramachandran S, Liu W, Shipley JM, Itohara S, Rogers JG et al. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2005)
[94]
Genetic polymorphisms predisposing to hyperhomocysteinemia in cardiac transplant patients. — Miriuka SG, Langman LJ, Evrovski J, Miner SE, D'Mello N, Delgado DH et al. Transplant international : official journal of the European Society for Organ Transplantation (2005)
[95]
Pre-transplant blood transfusion and cyclosporin A induce long-term hamster cardiac xenograft survival in immunocompetent rats. — Vriens PW, Stoot JH, van der Steenhoven TJ, Hoyt G, Bouwman E, Robbins RC Xenotransplantation (2005)
[96]
The effect of recipient cytokine gene polymorphism on cardiac transplantation outcome. — Gourley IS, Denofrio D, Rand W, Desai S, Loh E, Kamoun M Human immunology (2004)
[97]
Relationship between endomyocardial biopsy score and cyclosporine 2-h post-dose levels (C) in heart transplant patients receiving anti-thymocyte globulin induction. — Cantarovich M, Giannetti N, Cecere R Clinical transplantation (2004)
[98]
Antibody deposition in rat heart which develops transplant vasculopathy in (donor x recipient) F1 environment. — Li Z, Kitagawa-Sakakida S, Horiguchi K, Tori M, Shirakura R Surgery today (2003)
[99]
Radioimmunometric assay of B-type natriuretic peptide (BNP) in heart transplantation: correlation between BNP determinations and biopsy grading of rejection. — Hervás I, Almenar L, Pérez-Pastor JL, Chirivella M, Osa A, Martínez-Dolz L et al. Nuclear medicine communications (2003)
[100]
Rejection of grafts with no H-2 disparity in TAP1 mutant mice: CD4 T cells are important effector cells and self H-2b class I molecules are target. — Suárez IM, Benvenutti LA, Noronh I, Van Kaer L, Kalil J, Coelho V Transplant immunology (2002)